End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.77 USD | -5.55% | -15.06% | +109.33% |
May. 16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
May. 10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
Financials (USD)
Sales 2024 * | 1.82M | Sales 2025 * | 1.98M | Capitalization | 662M |
---|---|---|---|---|---|
Net income 2024 * | -63M | Net income 2025 * | -88M | EV / Sales 2024 * | 191 x |
Net cash position 2024 * | 314M | Net cash position 2025 * | 518M | EV / Sales 2025 * | 72.5 x |
P/E ratio 2024 * |
-10.3
x | P/E ratio 2025 * |
-8.67
x | Employees | 53 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.16% |
1 day | -5.55% | ||
1 week | -15.06% | ||
Current month | +1.97% | ||
1 month | +1.26% | ||
3 months | -14.56% | ||
6 months | +86.07% | ||
Current year | +109.33% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 22.55 | +3.58% | 122,810 |
24-05-23 | 21.77 | -5.55% | 248,815 |
24-05-22 | 23.05 | -6.19% | 79,480 |
24-05-21 | 24.57 | -3.50% | 86,647 |
24-05-20 | 25.46 | -0.66% | 48,035 |
End-of-day quote Nasdaq, May 22, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+109.33% | 662M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.31% | 21.78B | |
-9.28% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- DNTH Stock